NCT04262492 International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
| NCT ID | NCT04262492 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stéphane Zuily |
| Condition | Antiphospholipid Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2020-10-21 |
| Primary Completion | 2030-04-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2020-10-21 with a primary completion date of 2030-04-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.
Eligibility Criteria
Inclusion Criteria: * Patient receiving a comprehensive information about the study, and not opposed to participate * Age ≥ 18 yo * Classification of definite APS according to revised Sapporo-Sydney criteria * Direct oral anticoagulant treatment prescribed during at least 6 months or with the possibility of follow-up of at least 6 months Exclusion Criteria: * Incomplete revised Sapporo-Sydney criteria * No data regarding the recurrent thrombosis * Pregnant woman * Age \< 18 yo
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04262492 clinical trial?
This trial is open to participants of all sexes, studying Antiphospholipid Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04262492 currently recruiting?
Yes, NCT04262492 is actively recruiting participants. Contact the research team at v.dufrost@chru-nancy.Fr for enrollment information.
Where is the NCT04262492 trial being conducted?
This trial is being conducted at Nancy, France.
Who is sponsoring the NCT04262492 clinical trial?
NCT04262492 is sponsored by Stéphane Zuily. The trial plans to enroll 500 participants.